Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Dry Eye Disease
NCT07128628Phase 2Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lifitegrast, perfluorohexyloctane in dry eye disease (DED), sponsored by Bausch + Lomb. Started Oct 2025; status: completed.
02
Drugs
lifitegrastperfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07128628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128628.